List of articles with "Hansa Biopharma"

Q3 2025 Financial Update

Q3 2025 Financial Update

Sweden Lund Hansa Biopharma imlifidase ConfIdeS Trial
Hansa Biopharma Milestone

Hansa Biopharma Milestone

Sweden Lund Hansa Biopharma imlifidase kidney transplantation
Hansa Biopharma Event

Hansa Biopharma Event

Sweden Lund Hansa Biopharma imlifidase Transplant Surgeons
Transplant Surgeons Event

Transplant Surgeons Event

Sweden Lund Hansa Biopharma imlifidase Transplant Surgeons
Imlifidase Phase 3 Results

Imlifidase Phase 3 Results

USA Lund Hansa Biopharma imlifidase ConfIdeS Trial
Hansa Biopharma Leadership

Hansa Biopharma Leadership

Sweden Leadership Lund Hansa Biopharma Corporate Affairs
Hansa Biopharma Growth

Hansa Biopharma Growth

Sweden Lund Hansa Biopharma Corporate Affairs Brian Gorman
Hansa Biopharma Q2 Update

Hansa Biopharma Q2 Update

Sweden financial results Lund Hansa Biopharma IDEFIRIX
Hansa Biopharma Q2 Update

Hansa Biopharma Q2 Update

Sweden Lund Hansa Biopharma IDEFIRIX Phase 3 Trials
Hansa Biopharma's New CMO

Hansa Biopharma's New CMO

Sweden Lund Hansa Biopharma Chief Medical Officer Richard Philipson
Dr. Richard Philipson CMO

Dr. Richard Philipson CMO

Sweden Lund Hansa Biopharma Chief Medical Officer Dr. Philipson
Hansa's Imlifidase Study

Hansa's Imlifidase Study

Sweden Lund kidney transplant Hansa Biopharma imlifidase
Hansa's Imlifidase Findings

Hansa's Imlifidase Findings

Sweden London Hansa Biopharma imlifidase ESOT Congress
Hansa at BIO 2025

Hansa at BIO 2025

Sweden Lund Hansa Biopharma Renée Aguiar-Lucander biotech investment
Hansa at BIO Convention

Hansa at BIO Convention

Sweden Lund Hansa Biopharma BIO Convention Renée Aguiar-Lucander
Imlifidase for GBS Insights

Imlifidase for GBS Insights

Sweden Lund Hansa Biopharma imlifidase GBS Treatment
Imlifidase in GBS Treatment

Imlifidase in GBS Treatment

Sweden Lund Hansa Biopharma imlifidase Guillain-Barré
New COO at Hansa

New COO at Hansa

Sweden Lund Hansa Biopharma IDEFIRIX Maria Törnsén
Törnsén Joins Hansa

Törnsén Joins Hansa

USA Lund Hansa Biopharma IDEFIRIX Maria Törnsén
Hansa Biopharma Q1 Results

Hansa Biopharma Q1 Results

Sweden financial results Lund Hansa Biopharma IDEFIRIX
Hansa Biopharma Q1 Results

Hansa Biopharma Q1 Results

Sweden Lund Hansa Biopharma IDEFIRIX HNSA-5487
Hansa Biopharma Reports

Hansa Biopharma Reports

Sustainability Sweden Lund Hansa Biopharma IDEFIRIX
Hansa's 2024 Reports

Hansa's 2024 Reports

Sweden Lund Hansa Biopharma IDEFIRIX HNSA-5487
Hansa Biopharma Phase 3 Study

Hansa Biopharma Phase 3 Study

Sweden Lund kidney transplant Hansa Biopharma IDEFIRIX
Hansa Biopharma Phase 3

Hansa Biopharma Phase 3

Sweden Lund kidney transplant Hansa Biopharma IDEFIRIX
Hansa Biopharma 2024 Insights

Hansa Biopharma 2024 Insights

Sweden financial results Lund Hansa Biopharma IDEFIRIX
Hansa Biopharma Growth

Hansa Biopharma Growth

Sweden Lund Hansa Biopharma financial report IDEFIRIX
Hansa Biopharma 2025 Event

Hansa Biopharma 2025 Event

Sweden gene therapy Lund Hansa Biopharma imlifidase
Hansa at JPM 2025

Hansa at JPM 2025

Sweden gene therapy Lund Hansa Biopharma imlifidase
Imlifidase GBS Study

Imlifidase GBS Study

Sweden Lund Hansa Biopharma imlifidase Guillain-Barré Syndrome
Hansa Biopharma Results

Hansa Biopharma Results

Sweden Lund Hansa Biopharma imlifidase Guillain-Barré
Hansa Biopharma Trial Update

Hansa Biopharma Trial Update

Sweden Lund Hansa Biopharma imlifidase Anti-GBM
Hansa Completes Trial Enrollment

Hansa Completes Trial Enrollment

Sweden Lund Hansa Biopharma imlifidase Autoimmune Disease
Gene Therapy Trial Launch

Gene Therapy Trial Launch

Sweden Lund Hansa Biopharma Genethon imlifidase
Trial Launch for Gene Therapy

Trial Launch for Gene Therapy

Sweden Lund Hansa Biopharma GNT-0003 Crigler-Najjar

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.